Ingelheim
The company headquarters of Boehringer Ingelheim are located in Ingelheim, Germany.
Search
Positive opinion Ingelvac CircoFLEX and Ingelvac PRRSFLEX EU
Boehringer Ingelheim receives positive opinion for the combined use of Ingelvac CircoFLEX® and Ingelvac PRRSFLEX EU® in the EU
ATM-Ranking-2021
Boehringer Ingelheim climbs two places. New early-stage research projects for disease areas relevant to low-to-middle income countries not reflected.
Brigimadlin
MDM2-p53 antagonist
2020-Positive-business-momentum-despite-COVID-19-impact
While stepping up its investments in R&D significantly, Boehringer Ingelheim achieved a solid business performance in 2020 despite the COVID-19 pandemic.
Boehringer-Ingelheim's-half-year-figures-2021
Press release on Boehringer Ingelheim's half-year figures 2021. Business development from January to June 2021.
bix_facilitates_global_partnerships
BI X focuses on partnerships to speed up the development of digital healthcare solutions
Interview Dr Mehdi Shahidi
Interview with Dr Mehdi Shahidi, Chief Medical Officer and Head of the Corporate Division Medicine at Boehringer Ingelheim
Immunomodulator
Immunomodulator
STING agonist (2nd generation)
Second generation STING agonist
TREM-1 Antibody
TREM-1 Antibody
Ezabenlimab
Ezabenlimab, PD-1 antibody
PD-1 antibody
PD-1 antibody
Survodutide (BI 456906)
Survodutide (BI 456906)
Phospholipid modulator
Phospholipid modulator
Vascular modulator
Vascular modulator
Brigimadlin (BI 907828)
Brigimadlin BI 907828
New cancer therapeutics collaboration with 3T Bio
Boehringer Ingelheim and 3T Biosciences collaborate to discover and develop next-generation cancer therapies to address high unmet patient needs
Brigimadlin (BI 907828)
Brigimadlin BI 907828
NDMA regulator
NDMA regulator
Boehringer Ingelheim announces collaboration with MabGenesis
Boehringer Ingelheim announces collaboration with MabGenesis to discover and develop novel monoclonal antibodies in canine
Anti-fibrotic agent
Anti-fibrotic agent
Lung Repair & Regeneration Video
Lung repair & regeneration research addresses fundamental changes to lung architecture and how these changes impact lung function.
Boehringer Ingelheim acquires a stake in SoundTalks
Boehringer Ingelheim acquires stake in SoundTalks NV, begins pilot programme
VSV-GP
VSV-GP